Technology | Chronic Total Occlusion (CTO)

XableCath Inc., announced that its XableCath blunt and abrasion tip catheters were cleared by the U.S. Food and Drug Administration (FDA) as peripheral crossing catheters. The catheters have been safely and successfully used to cross challenging lesions in both arterial chronic total occlusions (CTOs) and chronic obstructive venous lesions. The recent crossing FDA clearance adds to the previous clearances for endovascular support.

Home January 30, 2019
Home
News | Heart Valve Technology

Thubrikar Aortic Valve Inc. announced the first human implant of the Optimum TAV using their transcatheter aortic valve implantation (TAVI) system.

Home January 29, 2019
Home
News | Heart Valve Technology

LivaNova PLC announced the publication of three separate studies highlighting the performance of its sutureless aortic valve, Perceval.

Home January 29, 2019
Home
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.
Feature | Stents | Dave Fornell, Editor

There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years ago ...

Home January 29, 2019
Home
Videos | Artificial Intelligence

DAIC Editor Dave Fornell takes a tour of some of the most interesting new artificial intelligence (AI) imaging ...

Home January 28, 2019
Home
News | Cardio-oncology

The American College of Cardiology host the third Advancing the Cardiovascular Care of the Oncology Patient course in Washington on Jan. 25-27, 2019. The event brought together top experts in both cardiology and oncology to review new and relevant science in this rapidly evolving field.

Home January 28, 2019
Home
News | EP Mapping and Imaging Systems

Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac imaging and mapping visualization system in persistent atrial fibrillation (AF) ablation procedures. Results presented at the 24th Annual AF Symposium, Jan. 24-26 in Boston, show the use of AcQMap resulted in 72.5 percent single-procedure freedom from AF at 12 months. Rigorous post-ablation monitoring showed 89.6 percent of the single-procedure patients experienced zero episodes of AF.

Home January 28, 2019
Home
An example of multimodality image fusion with live angiography to enhance soft-tissue visualization during complex procedures. This example is from Siemen's new TrueFusion software released in 2018. Advances in angiography imaging.
Feature | Angiography | Dave Fornell, Editor

There are a few recent trends in X-ray angiography imaging systems that hospitals should be aware of if they are looking ...

Home January 28, 2019
Home
News | Heart Valve Technology

Lenox Hill Hospital is the first hospital in New York City to successfully implant Abbott’s Tendyne transcatheter mitral valve replacement (TMVR) system to replace a leaky heart valve. The procedure was performed as part of a national clinical trial testing the safety and efficacy of the device as an alternative to invasive open heart surgery.

Home January 28, 2019
Home
News | Drug-Eluting Balloons

Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated with Philips’ Stellarex Drug-Coated Balloon (DCB) in above-the-knee (ATK) studies, which the company said reinforces the strong safety profile of Stellarex. The independent, third-party pooled analysis demonstrated low mortality rates through three years after the treatment with no device-related deaths.

Home January 28, 2019
Home
Videos | Cardiac Imaging

DAIC Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies displayed on the ...

Home January 26, 2019
Home
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor

The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003 ...

Home January 25, 2019
Home
News | Artificial Intelligence

January 25, 2019 — Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad ...

Home January 25, 2019
Home
News | Peripheral Artery Disease (PAD)

January 25, 2019 — Profusa announced promising clinical data from two studies evaluating the company's Lumee Oxygen ...

Home January 25, 2019
Home
Videos | Heart Valve Technology

Joe Cleveland, M.D., professor of cardiothoracic surgery, at the University of Colorado Hospital, offers a cardiac ...

Home January 25, 2019
Home
Subscribe Now